Targeted Therapy
Approved for: NSCLC
Biomarker: RET
Pralsetinib (Gavreto) is approved for non-small cell lung cancer (NSCLC) that has a RET fusion gene and is metastatic. It is used in adults.
FDA-Approved Lung Cancer Treatments
Pralsetinib (Gavreto)
I want to give in honor of...
name or relation
Donation Amount
other amount